ModernMedicine Resource Center More Topics

Hot Topics in Prostate Cancer

Has ordering of PSA screening dropped among PCPs?An examination of data involving more than 63,000 PSA tests ordered by primary care physicians reveals some surprising findings.
Upbringing, socioeconomic status linked to PCaA recent study shows children born to high-status parents have a higher incidence rate of developing prostate and other cancers in later life.
Delay from biopsy to RP: Who is at risk of recurrence?The risk of prostate cancer relapse after radical prostatectomy increases with lengthening delay between diagnosis and surgery. The impact, however, is significant only in high-risk patients, and even in those men, there may be a window of up to 12 months during which it may be relatively safe to postpone surgery, reported researchers from Milan, Italy.
There’s something about PSA: Ben Stiller fights the good fightUrologist Henry Rosevear, MD, discusses actor Ben Stiller's recent blog post that credits PSA tests for saving his life after he was diagnosed with prostate cancer and the urologic community's surprising reaction to the article.
Prostate Ca surveillance study has global implicationsA new study revealing 91% of very low-risk and 74% of low-risk prostate cancer patients in Sweden choose active surveillance should be a benchmark for the use of the management strategy in the U.S. and elsewhere in the world, the study’s authors say.
Large prostate Ca study evaluates RP, radiation, monitoringNearly 100% of patients with clinically localized prostate cancer, detected by PSA testing, survive at an average 10 years’ follow-up, regardless of whether they had active monitoring, radical prostatectomy, or radiotherapy, according to new study results.
SBRT yields excellent Ca control, low rate of severe toxicityResults from a multicenter study show progression-free survival in 97% of low- and intermediate-risk prostate cancer patients.
Researchers ID markers of resistance to two PCa therapiesFindings from a recent study indicate that CTCs detected in blood have the potential to reveal important genetic information that could guide treatment selection.
Test predicts PCSM at 10 years post prostatectomyNew research suggests that urologists can use the Decipher genetic test (GenomeDx Biosciences) to improve predictions of death risk from prostate cancer at10 years after prostatectomy.
HIFU results in low morbidity, QoL preservationAnother study suggests that hemiablation with high-intensity focused ultrasound is a promising treatment for unilateral localized prostate cancer.